For the quarter ending 2025-09-30, APTOF had $339K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -5,123 | -12,586 |
| Stock-based compensation | 44 | 391 |
| Accounts payable, related party | - | 0 |
| Depreciation of property and equipment | 11 | 7 |
| Loss on disposal of property and equipment | 0 | 0 |
| Amortization of right-of-use assets | 100 | 194 |
| Interest on lease liabilities | 8 | 21 |
| Interest on loan payable to related parties | 220 | 276 |
| Prepaid expenses | 156 | -396 |
| Other assets | 366 | 1,470 |
| Operating lease payments | 116 | 229 |
| Related party payable | 0 | - |
| Accounts payable | 198 | 1,621 |
| Accrued liabilities | -610 | 2,641 |
| Cash used in operating activities | -7,411 | -8,738 |
| Proceeds from loans payable with related parties | 7,750 | 2,600 |
| Repayment of loan with related party | 0 | 100 |
| Issuance of common shares and warrants-Registered Direct Offering | 0 | 0 |
| Issuance of common shares and warrants-January Two Thousand And Twenty Four Public Offering | 0 | 0 |
| Issuance of common shares and warrants-Hanmi Private Placement | 0 | 0 |
| Proceeds from issuance of common stock-Committed Equity Facility | 0 | 0 |
| Proceeds from issuance of common stock-The2022Atm Offering | 0 | 0 |
| Proceeds from issuance of common stock-The2025ATMOffering | 0 | 828 |
| Proceeds from issuance of common stock-Employee Stock Purchase Plan | 0 | 1 |
| Cash provided by financing activities | 7,750 | 3,329 |
| Disposal of property and equipment | 0 | 0 |
| Cash provided by investing activities | 0 | 0 |
| Decrease in cash, cash equivalents and restricted cash and restricted cash equivalents | 339 | -5,409 |
| Cash and cash equivalents at beginning of period | 6,707 | - |
| Cash and cash equivalents at end of period | 1,637 | - |
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)